News

Centauri is excited to announce that we have been selected to receive a £1M grant under the first round of @PACE-AMR funding which will support the continued development of our novel immunotherapeutic platform. Founded in 2023 by LifeArc, Innovate UK and Medicines Discovery Catapult, PACE is a new and comprehensive approach to tackling one of the world’s most complex health challenges: antimicrobial resistance (AMR). We are proud of the team’s efforts to progress this platform and excited to expand our pipeline with this additional funding from PACE.

Please see full press release here.